Ordering Recommendation

Screen for 21-hydroxylase deficiency, the most common congenital adrenal insufficiency.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Collect between 6-10 a.m.

Collect

Serum separator tube or green (sodium or lithium heparin). Also acceptable: Pink (K2EDTA).

Specimen Preparation

Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1.8 mL serum or plasma to an ARUP Standard Transport Tube and freeze immediately. (Min: 0.9 mL)

Storage/Transport Temperature

CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions

Refrigerated or room temperature specimens.

Remarks
Stability

After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 6 months

Methodology

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-5 days

Reference Interval

Test Number
Components
Reference Interval
  17-Hydroxyprogesterone, HPLC-MS/MS
Age
Male (ng/dL)
Female (ng/dL)
Premature (26-28 weeks) 124-841 124-841
Premature (29-35 weeks) 26-568 26-568
Full term Day 3 7-77 7-77
4 days-30 days Less than 200 7-106
1 month-2 months Less than 200 13-106
3 months-5 months 3-90 13-106
6 months-1 year Less than or equal to 148 Less than or equal to 148
2-3 years Less than or equal to 228 Less than or equal to 256
4-6 years Less than or equal to 208 Less than or equal to 299
7-9 years Less than or equal to 63 Less than or equal to 71
10-12 years Less than or equal to 79 Less than or equal to 129
13-15 years 9-140 9-208
16-17 years 24-192 Less than or equal to 178
18 years and older Less than 139 Less than 207
Follicular Not Applicable 15-70
Luteal Not Applicable 35-290
Tanner Stage I Less than or equal to 62 Less than or equal to 74
Tanner Stage II Less than or equal to 104 Less than or equal to 164
Tanner Stage III Less than or equal to 151 13-209
Tanner Stage IV-V 20-173 7-170

  17-Hydroxypregnenolone Quant, MS/MS, Ser
Age Male (ng/dL) Female (ng/dL)
Premature (26-28 weeks) 1219-9799 1219-9799
Premature (29-36 weeks) 346-8911 346-8911
Full Term (1-5 months) 229-3104 229-3104
6-12 months Less than or equal to 917 Less than or equal to 917
13-23 months Less than or equal to 592 Less than or equal to 592
2-4 years Less than or equal to 249 Less than or equal to 280
5-6 years Less than or equal to 319 Less than or equal to 350
7-9 years Less than or equal to 187 Less than or equal to 212
10-12 years Less than or equal to 392 Less than or equal to 398
13-15 years 35-465 Less than or equal to 407
16-17 years 32-478 Less than or equal to 423
18 years and older Less than 442 Less than 226
Tanner Stage I Less than or equal to 208 Less than or equal to 235
Tanner Stage II Less than or equal to 355 Less than or equal to 367
Tanner Stage III Less than or equal to 450 Less than or equal to 430
Tanner Stage IV & V 35-478 Less than or equal to 412

  Androstenedione by TMS
Age
Male (ng/mL)
Female (ng/mL)
Premature Infants (26-28 weeks Day 4) 0.92-2.82 0.92-2.82
Premature Infants (31-35 weeks Day 4) 0.80-4.46 0.80-4.46
Full Term Infants (1-7 days) 0.20-2.90 0.20-2.90
8-30 days 0.18-0.80 0.18-0.80
1-5 months 0.06-0.68 0.06-0.68
6-24 months 0.03-0.15 Less than 0.15
2-3 years Less than 0.11 Less than 0.16
4-5 years 0.02-0.17 0.02-0.21
6-7 years 0.01-0.29 0.02-0.28
8-9 years 0.03-0.30 0.04-0.42
10-11 years 0.07-0.39 0.09-1.23
12-13 years 0.10-0.64 0.24-1.73
14-15 years 0.18-0.94 0.39-2.00
16-17 years 0.30-1.13 0.35-2.12
18-39 years 0.33-1.34 0.26-2.14
40 years and older 0.23-0.89 0.13-0.82
Premenopausal Not Applicable 0.26-2.14
Postmenopausal Not Applicable 0.13-0.82
Tanner Stage I 0.04-0.32 0.05-0.51
Tanner Stage II 0.08-0.48 0.15-1.37
Tanner Stage III 0.14-0.87 0.37-2.24
Tanner Stage IV-V 0.27-1.07 0.35-2.05

  Dehydroepiandrosterone by TMS
Age Male (ng/mL) Female (ng/mL)
Premature Less than 40 Less than 40
0-1 days Less than 11 Less than 11
2-6 days Less than 8.7 Less than 8.7
7 days-1 month Less than 5.8 Less than 5.8
1-5 months Less than 2.9 Less than 2.9
6-24 months Less than 2.5 Less than 1.99
2-3 years Less than 0.63 Less than 0.85
4-5 years Less than 0.95 Less than 1.03
6-7 years 0.06-1.93 Less than 1.79
8-9 years 0.10-2.08 0.14-2.35
10-11 years 0.32-3.08 0.43-3.78
12-13 years 0.57-4.10 0.89-6.21
14-15 years 0.93-6.04 1.22-7.01
16-17 years 1.17-6.52 1.42-9.00
18-39 years 1.33-7.78 1.33-7.78
40 years and older 0.63-4.70 0.63-4.70
Postmenopausal Not Applicable 0.60-5.73
Tanner Stage I 0.11-2.37 0.14-2.76
Tanner Stage II 0.37-3.66 0.83-4.87
Tanner Stage III 0.75-5.24 1.08-7.56
Tanner Stage IV-V 1.22-6.73 1.24-7.88

Interpretive Data

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

82157; 83498; 84143; 82626

Components

Component Test Code* Component Chart Name LOINC
0092332 17-Hydroxyprogesterone, HPLC-MS/MS 1668-3
0092333 17-Hydroxypregnenolone Quant, MS/MS, Ser 6765-2
2001639 Androstenedione by TMS 1854-9
2001641 Dehydroepiandrosterone by TMS 2193-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 17-Hydroxypregnenolone (CAH 21 Hydroxylase Deficiency Panel)
  • 17-Hydroxyprogesterone (CAH 21 Hydroxylase Deficiency Panel)
  • Androstenedione (CAH 21 Hydroxylase Deficiency Panel)
  • Dehydroepiandrosterone (DHEA) (CAH 21 Hydroxylase Deficiency Panel)
Congenital Adrenal Hyperplasia Panel, 21-Hydroxylase Deficiency